Together, these findings suggest that the distinct co-expression patterns associated with the inhibitory receptor FCRL5 may reflect the ability of the CD11c+ B cells to respond to activating signals within their unique immune environments, shaping the dysregulation in MG subtypes. The gene discussed is FCRL5; the disease is myasthenia gravis.